Bone Metastasis Market
Bone Metastasis Market: Information by Type, Diagnosis (Biopsy, Blood Test, Imaging), Treatment (Medical Therapies, Surgery, Medication), End-User and Regional Outlook - Forecast Till 2026
Market Overview
The global bone metastasis market was valued at around USD 13,410 million in 2017 and is expected to grow at a CAGR of 8.1% in the forecast period.
According to the American Cancer Society, in 2018 around 164,690 new cases and about 29,430 deaths occurred from prostate cancer. The increased prevalence of breast cancer is driving the growth of the market. As per the Breast Cancer Association, in 2018, 266,120 new cases of invasive breast cancer were diagnosed in women in the U.S. Moreover, the other factors boosting the growth of the market include the increasing geriatric population, growing healthcare expenditure, and rising R&D expenses by key players.
Cancers such as prostate, breast, and lung are most likely to spread to the bone. The spread of any type of cancer to bone can result in severe pain, hypercalcemia, pathologic fracture, and spinal cord or nerve root compression. According to the Modern Medicine Network, approximately 30% to 60% of patients with advanced lung cancer develop bone metastases. Moreover, some of the symptoms of the disease include Urinary incontinence, bowel incontinence, and hypercalcemia.
Market Snapshot
Segmental Analysis
The global bone metastasis market is segmented by type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others. Osteolytic bone metastasis is expected to leading segment during the forecast period.
Based on the diagnosis, the market is segmented into biopsy, blood test, imaging, and others.
On the basis of treatment, the market is segmented into medical therapies, surgery, medication, and others.
Based on the end-user the market is segmented into hospitals & clinics, diagnostic centers, pharmacies, and ambulatory surgical centers.
Regional Analysis
The global bone metastasis market is divided into major four regions such as North America, Europe, Asia-Pacific (APAC), Latin America, Middle East & Africa.
North America dominates the market due to the presence of a well-developed healthcare sector and the growing prevalence of breast cancer in the region. Increasing research on cancer stem cells is boosting the demand of the market in the future.
Europe is likely to stand second in the market owing to the increased prostate cancer, government support, reimbursement policies in this region. According to the Cancer Research U.K, in males prostate cancer is the most common cancer, with around 47,200 new cases in 2015. Prostate cancer accounts for 26% of all new cancer cases in males in the UK.
Moreover, Asia Pacific is predicted to be the fastest-growing region due to the presence of a developing healthcare sector and the growing prevalence of cancer are major drivers for the growth of the market. As per the American Cancer Society, 56% of the world’s population (3.8 billion), contributes 44% of all cancer cases (6.4 million out of 14.1 million) and 51% of all cancer deaths (4.3 million out of 8.2 million) worldwide, with China representing most of the cancer burden. It is estimated that China alone accounts for 50% of all cancer cases in this region.
Additionally, the Middle East and Africa hold the least share, this is mainly due to the presence of poor economies, stringent government policies, and lack of healthcare services, especially in the African region.
Top Key Players of Bone Metastasis Market
List of key bone metastasis market companies profiled
- Bayer AG
- Merck & Co. Inc.
- Pfizer Inc.
- Novartis AG
- Pharmalucence Inc.
- Koninklijke Philips N.V.
- GENERAL ELECTRIC
- Siemens AG
- TOSHIBA CORPORATION
Report Scope
| Report Metric | Details |
|---|---|
| CAGR | 8.1% |
| Forecast Period | 2023-2031 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
| Segments Covered |
|
| Geographies Covered |
|
Recent Developments
In January 2019, Exelixis received FDA approval for Cabozantinib (Cabometyx), which improves survival in renal cell carcinoma (RCC) Patients with Bone Metastases.
Bone Metastasis Market Segmentation
By Type
- Osteolytic Bone Metastasis
- Osteoblastic Bone Metastasis
- Mixed Bone Metastasis
- Others
By Diagnosis
- Biopsy
- Blood Test
- Imaging
- X-ray
- Bone Scintigraphy
- Computerized Tomography
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Others
- Others
By Treatment
-
Medical Therapies
- Chemotherapy
- Targeted Therapy
- Hormone Therapy
- Ablation Therapy
- Others
-
Surgery
- Vertebroplasty
- Kyphoplasty
- Others
-
Medication
- Pain Medications
- Bone Building Medications
- Others
-
Others
By End-User
- Hospitals & Clinics
- Diagnostic Centers
- Pharmacies
- Ambulatory Surgical Centers
By Regions
- North America
- Europe
- Asia-Pacific
- LAMEA
USD 995
Purchase Benefits
- Eligible for a free updated report next year
- Completely customizable scope
- 30% discount on your next purchase
- Dedicated account manager
- Query resolution within 24 hours
- Permission to print the report
Report Benefits
- Develop business strategies by understanding the trends shaping and driving the Market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track sales in the global and country-specific Market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
